Tilray (TLRY) to Report Q4 Earnings: What's in the Cards?
Zacks Investment Research | Jul 23, 2021 04:47AM ET
Tilray (NASDAQ:TLRY), Inc. Earnings ESP Filter .
Earnings ESP: Earnings ESP for Tilray is +14.47%.
Zacks Rank: It currently carries a Zacks Rank #3.
h3 Factors at Play/h3Tilray is a leading global cannabis-lifestyle and consumer packaged goods company.
In May 2021, the company completed its previously announced business combination with Aphria (NASDAQ:APHA). Each Aphria shareholder received 0.8381 of a Tilray share for each Aphria common share held on Apr 30, 2021. The combined company is now one of the leading cannabis-focused consumer packaged goods companies, with the largest global geographic footprint in the industry.
This will be the first quarter of reporting post the merger. Tilray has a strong consumer packaged goods presence in the United States. The combination with Aphria has strengthened its infrastructure with the addition of SweetWater, a leading cannabis lifestyle branded craft brewer. Performance in the quarter under review has likely got a boost with the incremental contribution.
In June 2021, Tilray announced the launch of a new medical cannabis brand, Symbios. Tilray also announced new high-potency, medical cannabis topicals under the Aphria brand designed to target inflammatory joint disease by regulating tissue inflammation when applied topically to the skin.
Revenues have likely shown a recovery as COVID-related lockdowns eased in Canada and Germany.
The new company expects to generate approximately $81 million of annual pre-tax cost synergies within eighteen months and plans to achieve cost synergies in the key areas of cultivation and production, cannabis and product purchasing, sales and marketing, and corporate expenses. Further updates on the same are awaited with the results.
h3 Share Price Performance/h3Tilray’s stock has surged 61.5% in the year so far against the industry ’s decline of 10.1%.
Image Source: Zacks Investment Research
Get The News You Want
Here are a few stocks you may want to consider, as our model shows that these have the right combination of elements to post an earnings beat this season.
Ironwood Pharmaceuticals Inc. the complete list of today’s Zacks #1 Rank stocks here .
AbbVie, Inc. ABBV has an Earnings ESP of +0.86% and a Zacks Rank #3.
Exact Sciences (NASDAQ:EXAS) EXAS has an Earnings ESP of +8.80% and a Zacks Rank #3.
Infrastructure Stock Boom to Sweep America
A massive push to rebuild the crumbling U.S. infrastructure will soon be underway. It’s bipartisan, urgent, and inevitable. Trillions will be spent. Fortunes will be made.
The only question is “Will you get into the right stocks early when their growth potential is greatest?”
Zacks has released a Special Report to help you do just that, and today it’s free. Discover 7 special companies that look to gain the most from construction and repair to roads, bridges, and buildings, plus cargo hauling and energy transformation on an almost unimaginable scale.
Download FREE: How to Profit from Trillions on Spending for Infrastructure >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Zacks Investment Research
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.